Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR003719)
Formula Reactant LBQ657 Product LCZ-696 Metabolite M7
Reactant Info Product Info
Metabolic Type Oxidation - Oxidationn
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Produce The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR010568 LCZ696 Sacubitrilat LBQ657 Unclear - Unclear LCZ696 [1]
MR003715 Sacubitril LBQ657 Hydrolysis - Ester hydrolysis LCZ-696 [2], [3], [4]
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR003716 LBQ657 LCZ-696 Metabolite M4 Unclear LCZ-696 [4]
MR003717 LBQ657 LCZ-696 Metabolite M5 Unclear LCZ-696 [4]
MR003718 LBQ657 LCZ-696 Metabolite M6 Oxidation - Oxidationn LCZ-696 [4]
MR003720 LBQ657 LCZ-696 Metabolite M8 Unclear LCZ-696 [4]
References
1 An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension
2 Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)
3 Dicarboxylic acid dipeptide neutral endopeptidase inhibitors
4 Disposition and metabolism of [(14)C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.